Menu
Transforming lives by developing innovative treatment for ocular disease that helps restore sight for life
Transforming lives by developing innovative treatment for ocular disease that helps restore sight for life
Theialife is a virtual late-clinical stage novel ophthalmology drug company founded on an unyielding commitment to develop innovative breakthrough drug therapies for ophthalmological applications that have unmatched potential to advance the existing standard of care to prevent sight deterioration, restore patient vision and enrich lives.
We have a portfolio of first-in-class molecules that address large-unmet vision-threatening retinal diseases that can lead to further complications, like retinal detachment or blindness.
Our lead asset, ND10 is poised to become the first oral therapy for early-onset-paediatric myopia and is set to enter global Phase III clinical trials in 2025.
20 years of real-world clinical usage in Denmark, with nil reported adverse effects.
Theialife’s commitment to innovation is reflected in our impressive metrics, demonstrating our impact in ophthalmology
People with vision impairement
People who have myopia
People with high myopia
Theialife is featured on the front cover of the coveted British Journal of Ophthalmology.
To learn more about the groundbreaking benefits of ND10 in the use of Myopia control and treatment in children, The British journal of Ophthalmology published a peer-reviewed article.
Theialife article is published in the International Journal of Ophthalmology.
Read our latest article on the “Role of ND10 in myopia prevention and control: a mini-review”
